Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy
about
Expression and extracellular release of a functional anti-trypanosome Nanobody® in Sodalis glossinidius, a bacterial symbiont of the tsetse flyProperties, production, and applications of camelid single-domain antibody fragmentsAn update on antibody-based immunotherapies for Clostridium difficile infectionClostridium difficile infection: molecular pathogenesis and novel therapeuticsSingle domain antibodies: promising experimental and therapeutic tools in infection and immunityNeutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domainEngineered single-domain antibodies with high protease resistance and thermal stabilityNovel camelid antibody fragments targeting recombinant nucleoprotein of Araucaria hantavirus: a prototype for an early diagnosis of Hantavirus Pulmonary SyndromeJoining the in vitro immunization of alpaca lymphocytes and phage display: rapid and cost effective pipeline for sdAb synthesisImmunological applications of single-domain llama recombinant antibodies isolated from a naïve library.Camelid nanobodies raised against an integral membrane enzyme, nitric oxide reductaseLlama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents.Delivery of a functional anti-trypanosome Nanobody in different tsetse fly tissues via a bacterial symbiont, Sodalis glossinidiusIn vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH).Engineered antibody variable and constant domains as therapeutic candidates.Pentavalent single-domain antibodies reduce Campylobacter jejuni motility and colonization in chickens.Protease-resistant single-domain antibodies inhibit Campylobacter jejuni motility.Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.Development and evaluation of single domain antibodies for vaccinia and the L1 antigenMultivalent anchoring and oriented display of single-domain antibodies on cellulose.Nanobody; an old concept and new vehicle for immunotargeting.Biotechnological applications of recombinant single-domain antibody fragments.Fundamentals and application of ordered molecular assemblies to affinity biosensing.Nanobodies as novel agents for disease diagnosis and therapy.Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications.Improving the targeting of therapeutics with single-domain antibodies.HypE-specific nanobodies as tools to modulate HypE-mediated target AMPylation.Antibody Fragments as Probe in Biosensor Development.Nanobodies As Tools to Understand, Diagnose, and Treat African Trypanosomiasis.Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis.Blocking of Histamine Release and IgE Binding to FcεRI on Human Basophils by Antibodies Produced in Camels.Enhancing Stability of Camelid and Shark Single Domain Antibodies: An Overview.Conjugation of biotin-coated luminescent quantum dots with single domain antibody-rhizavidin fusions.Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.Highly efficient and easy protease-mediated protein purification.Single-Domain Antibodies and the Promise of Modular Targeting in Cancer Imaging and Treatment.Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease.Enhanced stabilization of a stable single domain antibody for SEB toxin by random mutagenesis and stringent selection.
P2860
Q21246029-9A517B0F-7CB6-4E73-8B42-6DEFED43F2F4Q24676749-2BDBA540-78A4-4DEB-BF12-5B2D0DDA53E7Q26740788-11A044CF-90E6-4122-A816-1474F34FB775Q26864237-4D7C7A90-037C-453D-8E5F-2BFEE5B432F2Q28248678-A2490306-8576-4FC7-9A44-F449A9B89C20Q28302768-24F8746D-600C-478B-A596-4DB1DE4CD4CEQ28478199-58B0C0E9-009D-4F66-A00E-0FC4A4089DBAQ28543136-ECB0A19F-1393-459A-9561-0A9A1DC78248Q29248081-0ED77A8D-852A-44DF-B080-E4805BEE761AQ33406065-1212BFCD-F074-45B9-9A7A-D2A48E4B058CQ33412211-68D2726F-08B3-4D92-BBAF-E33724CE6C3CQ33526251-56F3A3C7-15AB-4437-AD3D-1036C34501C7Q34502952-F1000A19-8705-4B6B-A092-41413B09C620Q34716360-5376BBAF-1631-4F9D-A200-AC8C7DA82BC1Q35044156-E9305B2F-9C7E-461F-A186-2D4007E1AD3BQ35082668-E0D5CB29-4230-4614-8DAE-FA87EC355742Q35151390-4A37D082-885F-4568-ADE7-87AF060B0510Q35155775-9801B497-CD0F-450A-8FB3-B42839168DE9Q35248202-93128622-DF65-4B0C-B92A-269424972AA4Q35741422-91E07395-A83F-49AD-A542-B7D3316ABEFEQ37829737-D27A5010-3E3E-48A1-A0E2-28569DF0FBA3Q37887077-A0E5260E-DE64-4423-89EC-FD122D094BF6Q37959261-712015A2-4558-4C90-BB44-1B6E314A4E8CQ38160835-DB2ADA87-F6D2-4D6C-B1F0-ED3462CB3A22Q38323786-937684E4-03EE-4797-8DB3-BEEE5F2CC156Q38675117-ACF3AA8C-C029-40A1-9516-BFCEA11D9680Q38910073-538911C4-9A9E-410D-992E-41AD12AD00A9Q39016494-C57024FC-F968-4053-9AD3-5F3CE7F98847Q39437960-CA0A1FC9-3720-463B-AD54-6D4D5B4D6DE3Q39793093-B7C4DC00-06EA-4320-AB0F-4C2E83FD3A66Q40580798-C28AB369-AE70-4229-BE33-D822994041D1Q41108385-71095693-26D7-4CC1-9674-BCFB20CE36C1Q41212173-9B0857EE-B4B4-4A54-B2CD-B6D5619F2772Q42697422-7E878CC8-8841-44E9-86C8-C7BBF00D1A02Q50237169-7B5E7072-08E2-4BBA-B66B-CFFFE5358A66Q52362264-1BC178CF-7BEE-4180-9244-207FEDC1AD8EQ52643911-92C7F12F-FDA3-4E23-B348-A5F02844CE1FQ53627592-C021DABE-490A-4594-98BF-0C5866E2BF41
P2860
Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Selection and optimization of ...... agments for oral immunotherapy
@ast
Selection and optimization of ...... agments for oral immunotherapy
@en
Selection and optimization of ...... agments for oral immunotherapy
@nl
type
label
Selection and optimization of ...... agments for oral immunotherapy
@ast
Selection and optimization of ...... agments for oral immunotherapy
@en
Selection and optimization of ...... agments for oral immunotherapy
@nl
prefLabel
Selection and optimization of ...... agments for oral immunotherapy
@ast
Selection and optimization of ...... agments for oral immunotherapy
@en
Selection and optimization of ...... agments for oral immunotherapy
@nl
P2093
P921
P3181
P1476
Selection and optimization of ...... agments for oral immunotherapy
@en
P2093
Harmsen MM
van Solt CB
van Zijderveld FG
van Zijderveld-van Bemmel AM
P2888
P304
P3181
P356
10.1007/S00253-005-0300-7
P407
P50
P577
2006-02-01T00:00:00Z
P6179
1027756420